BioLife Solutions (BLFS) Stock Price, News & Analysis

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1 year price targets for BioLife Solutions' stock. Their BLFS share price targets range from $22.00 to $25.00. On average, they expect the company's stock price to reach $23.40 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price.
View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts.

BioLife Solutions' stock was trading at $16.25 at the beginning of 2024. Since then, BLFS shares have decreased by 6.8% and is now trading at $15.14.
View the best growth stocks for 2024 here.

BioLife Solutions saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,200,000 shares, an increase of 5.6% from the March 15th total of 3,030,000 shares. Based on an average daily trading volume, of 412,500 shares, the short-interest ratio is presently 7.8 days.
View BioLife Solutions' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BLFS earnings forecast.

BioLife Solutions, Inc. (NASDAQ:BLFS) posted its quarterly earnings results on Thursday, February, 29th. The medical equipment provider reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. The medical equipment provider earned $32.73 million during the quarter, compared to analysts' expectations of $32.70 million. BioLife Solutions had a negative net margin of 46.37% and a negative trailing twelve-month return on equity of 13.36%.

BioLife Solutions issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $95.5 million-$100.0 million, compared to the consensus revenue estimate of $121.4 million.

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

BioLife Solutions' stock is owned by a number of institutional and retail investors. Top institutional investors include Register Financial Advisors LLC (0.01%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard and Troy Wichterman.
View institutional ownership trends.

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.